Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 6, 2009

Mitsubishi Tanabe Signs On Affectis for Discovery Work for Antidepressants

  • Mitsubishi Tanabe Pharma (MTPC) will use Affectis Pharmaceuticals’ behavioral pharmacology expertise and technology in its drug discovery efforts. Affectis will receive research fees and is eligible to developmental milestones. 
     
    MTPC’s ongoing drug discovery program is reportedly based on a novel depression target that Affectis helped validate in a previous collaboration. The deal, which was inked in February 2005, covered the use of Affectis’ Behavioural Interference™ platform.

    Under the new agreement, MTPC will continue to utilize this technology and Affectis’ expertise. Affectis has two antidepressant discovery programs and one Phase II candidate for depression.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »